Toleranzia AB (TOL.ST)
SEK 0.61
(0.33%)
SEK 0.61
(0.33%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 50.92 Million SEK | 43.98% |
| 2022 | 35.36 Million SEK | 28.19% |
| 2021 | 27.58 Million SEK | 114.18% |
| 2020 | 12.88 Million SEK | 85.36% |
| 2019 | 6.94 Million SEK | 62.45% |
| 2018 | 4.27 Million SEK | 68.93% |
| 2017 | 2.53 Million SEK | -30.26% |
| 2016 | 3.63 Million SEK | 5400.72% |
| 2015 | 66.01 Thousand SEK | -78.64% |
| 2014 | 309 Thousand SEK | -90.24% |
| 2013 | 3.16 Million SEK | -49.18% |
| 2012 | 6.22 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | - SEK | -100.0% |
| 2024 Q2 | 7.41 Million SEK | 50.78% |
| 2024 Q1 | 4.91 Million SEK | -56.95% |
| 2023 Q2 | 19.65 Million SEK | 94.03% |
| 2023 Q4 | 11.42 Million SEK | 14.16% |
| 2023 Q1 | 10.13 Million SEK | -23.76% |
| 2023 FY | 50.92 Million SEK | 43.98% |
| 2023 Q3 | 10 Million SEK | -49.11% |
| 2022 Q2 | 11.57 Million SEK | 43.3% |
| 2022 Q3 | 2.42 Million SEK | -79.09% |
| 2022 Q4 | 13.28 Million SEK | 448.91% |
| 2022 FY | 35.36 Million SEK | 28.19% |
| 2022 Q1 | 8.07 Million SEK | 40.11% |
| 2021 Q4 | 5.76 Million SEK | -21.22% |
| 2021 Q2 | 7.84 Million SEK | 17.96% |
| 2021 FY | 27.58 Million SEK | 114.18% |
| 2021 Q1 | 6.65 Million SEK | 68.44% |
| 2021 Q3 | 7.31 Million SEK | -6.76% |
| 2020 FY | 12.88 Million SEK | 85.36% |
| 2020 Q2 | 5.31 Million SEK | 173.88% |
| 2020 Q4 | 3.95 Million SEK | 137.08% |
| 2020 Q3 | 1.66 Million SEK | -68.65% |
| 2020 Q1 | 1.94 Million SEK | -41.98% |
| 2019 Q3 | 897.55 Thousand SEK | -51.83% |
| 2019 FY | 6.94 Million SEK | 62.45% |
| 2019 Q2 | 1.86 Million SEK | 120.89% |
| 2019 Q1 | 843.6 Thousand SEK | -34.55% |
| 2019 Q4 | 3.34 Million SEK | 272.66% |
| 2018 Q4 | 1.28 Million SEK | 54.59% |
| 2018 FY | 4.27 Million SEK | 68.93% |
| 2018 Q3 | 833.73 Thousand SEK | -30.82% |
| 2018 Q2 | 1.2 Million SEK | 26.87% |
| 2018 Q1 | 949.99 Thousand SEK | 24.39% |
| 2017 Q2 | 685.37 Thousand SEK | 21.51% |
| 2017 FY | 2.53 Million SEK | -30.26% |
| 2017 Q3 | 519.19 Thousand SEK | -24.25% |
| 2017 Q1 | 564.02 Thousand SEK | -17.31% |
| 2017 Q4 | 763.73 Thousand SEK | 47.1% |
| 2016 Q1 | 788.03 Thousand SEK | 19700775.0% |
| 2016 FY | 3.63 Million SEK | 5400.72% |
| 2016 Q4 | 682.12 Thousand SEK | -20.47% |
| 2016 Q3 | 857.65 Thousand SEK | -4.52% |
| 2016 Q2 | 898.22 Thousand SEK | 13.98% |
| 2015 Q2 | 443.83 Thousand SEK | 572.46% |
| 2015 Q1 | 66 Thousand SEK | -82.76% |
| 2015 Q3 | 624.2 Thousand SEK | 40.64% |
| 2015 FY | 66.01 Thousand SEK | -78.64% |
| 2015 Q4 | 4.00 SEK | -100.0% |
| 2014 FY | 309 Thousand SEK | -90.24% |
| 2014 Q4 | 382.94 Thousand SEK | 0.0% |
| 2013 FY | 3.16 Million SEK | -49.18% |
| 2012 FY | 6.22 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 1.29 Billion SEK | 96.073% |
| Enzymatica AB (publ) | 50.9 Million SEK | -0.031% |
| Enorama Pharma AB (publ) | 1.35 Million SEK | -3649.632% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | - SEK | -Infinity% |
| Nanexa AB (publ) | 29.32 Million SEK | -73.628% |
| Newbury Pharmaceuticals AB (publ) | 36.82 Million SEK | -38.261% |
| ODI Pharma AB | 22.44 Million SEK | -126.844% |
| Orexo AB (publ) | 638.8 Million SEK | 92.029% |
| Probi AB (publ) | 627.68 Million SEK | 91.888% |
| Swedencare AB (publ) | 2.32 Billion SEK | 97.81% |
| Swedish Orphan Biovitrum AB (publ) | 22.12 Billion SEK | 99.77% |
| Vivesto AB | 1.01 Million SEK | -4916.749% |